Ireland Pharma and Health Trends: October 2026 edition

Key findings

Figures describe the data. They do not explain causes and they are not forecasts. Each figure names its own reference period, because sources publish with different lags.

• Ireland exported EUR 5,971 million of medicinal and pharmaceutical products (SITC 54) in August 2026. This was EUR 818 million (12.1%) less than in July 2026 and EUR 513 million (7.9%) less than in August 2025. Provisional. Source: Eurostat (European Commission), Comext dataset DS-059331. Details
• Exports to the United States were EUR 2,150 million in August 2026, down 21.3% on July 2026 (EUR 2,732 million) and down 9.9% on August 2025 (EUR 2,387 million). Provisional. Source: Central Statistics Office, Ireland. Details
• The seasonally adjusted production index for the modern sector, which includes pharmaceuticals, was 115.7 in August 2026, against 117.8 in July 2026 (down 1.8%) and 141.2 in August 2025 (down 18.1%). Provisional. Source: Central Statistics Office, Ireland (PxStat tables MIM05, MIA05, EHQ15, EHQ58, AIA30, PMMA01-PMMA07, PMMA10, PMMA11, PMMA13). Details
• 692,524 people were waiting for a first outpatient appointment at the NTPF snapshot of 24 September 2026. This was 66,003 (10.5%) more than at 25 September 2025 and 4,685 (0.7%) more than at 27 August 2026. Source: National Treatment Purchase Fund (NTPF), Ireland. Details
• 43,288 people were waiting for GI endoscopy on 24 September 2026, 28.1% more than on 25 September 2025 (33,786). Source: National Treatment Purchase Fund (NTPF), Ireland. Details
• 64,077 people were waiting 18 months or more across the three NTPF lists on 24 September 2026, against 54,104 a year earlier (up 18.4%). A person on more than one list is counted once per list. Source: National Treatment Purchase Fund (NTPF), Ireland. Details
• 81 medicines received an EU marketing authorisation in the 12 months to September 2026. The figure was 107 in the 12 months to September 2025, a fall of 26 (24.3%). Source: European Medicines Agency. Details
• 132 ClinicalTrials.gov studies with a site in Ireland had a start date in the 12 months to June 2026, against 137 in the 12 months to June 2025 (down 5, 3.6%). Late registrations still add to recent months. Provisional. Source: U.S. National Library of Medicine. Details
• These studies were 1.54% of the 8,584 studies with a European site starting in the same period, against 1.46% in the 12 months to June 2025 (up 0.08 percentage points). Provisional. Source: U.S. National Library of Medicine. Details
• 114.8 million prescription items were dispensed in the community in England in July 2026, 3.1% more than in July 2025 (111.4 million). Source: NHS Business Services Authority (NHSBSA), Open Data Portal, dataset "Prescription Cost Analysis (PCA) Monthly Administrative Data". Details
• 39 health contract awards were published on eTenders in September 2026, 25 (39.1%) fewer than in August 2026 (64) and 8 (25.8%) more than in September 2025 (31). Source: Office of Government Procurement (OGP), Ireland. Details
• Irish chemical and pharmaceutical facilities reporting to the EEA transferred 253,821 tonnes of waste off site in 2024 (n = 2,301 records), against 508,328 tonnes in 2023 (down 50.1%). 2024 is the latest reporting year in the data. Source: European Environment Agency (EEA), Industrial Reporting under the Industrial Emissions Directive 2010/75/EU and the E-PRTR Regulation (EC) No 166/2006 (Irish data reported by the EPA). Details

Medicines and approvals

Medicines and approvals: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Human medicines first authorised in Ireland (HPRA register)Unit: products	16 productsn = 16	September 2026	26 productsAugust 2026	55 productsSeptember 2025	−10	−39	Provisional Small n
EU marketing authorisations for medicines evaluated by EMA, 12 monthsUnit: medicines	81 medicines	12 months to September 2026	86 medicines12 months to August 2026	107 medicines12 months to September 2025	−5 (−5.8%)	−26 (−24.3%)	None
EU orphan designations, 12 monthsUnit: designations	165 designations	12 months to July 2026	168 designations12 months to June 2026	150 designations12 months to July 2025	−3 (−1.8%)	+15 (+10.0%)	Lag 2 months
US FDA original approvals of new drug and biologic applications (NDA and BLA)Unit: applications	15 applicationsn = 15	September 2026	12 applicationsAugust 2026	14 applicationsSeptember 2025	+3	+1	Small n

Definitions, notes and sources: medicines and approvals

Human medicines first authorised in Ireland (HPRA register)

Products on the HPRA human medicines register whose authorised_date falls in the month. The register lists products authorised now (or with transfer pending), so products later withdrawn drop out of earlier months.

Note: Survivorship: the register is a current list, so counts for past months can fall as products are withdrawn.

Note: The HPRA can add products to the register some weeks after authorisation; the latest month can rise in later editions.

Provisional: The HPRA can add products to the register some weeks after authorisation, so the latest month can rise in later editions.

Source: Health Products Regulatory Authority. Dataset hpra_medicines, collected 19 October 2026. Data complete from January 1975 to September 2026.

EU marketing authorisations for medicines evaluated by EMA, 12 months

Medicines in EMA's list of human medicines whose marketing authorisation date falls in the 12 months ending with the reference month (any current status, including later withdrawn).

Note: Monthly counts are small (often under 15), so a 12-month total is used.

Source: European Medicines Agency. Dataset ema_medicines, collected 19 October 2026. Data complete from November 1995 to September 2026.

EU orphan designations, 12 months

EU orphan designations whose designation date falls in the 12 months ending with the reference month, excluding negative outcomes (status Negative).

Note: EMA publishes designation pages some weeks after the European Commission decision; a two-month lag is applied.

Source: European Medicines Agency. Dataset ema_orphans, collected 19 October 2026. Data complete from September 2000 to July 2026.

US FDA original approvals of new drug and biologic applications (NDA and BLA)

Drugs@FDA applications of type NDA or BLA whose original approval date falls in the month. Generic applications (ANDA) are excluded.

Note: Comparator series (United States).

Source: U.S. Food and Drug Administration (openFDA). Dataset fda_approvals, collected 19 October 2026. Data complete from March 1939 to September 2026.

Shortages and safety

Shortages and safety: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Medicine shortages first published by EMA, 12 monthsUnit: shortage entries	16 shortage entriesn = 16	12 months to September 2026	14 shortage entries12 months to August 2026	13 shortage entries12 months to September 2025	+2	+3	Small n
MHRA drug and device alerts and Drug Safety Update articles (UK)Unit: items	12 itemsn = 12	September 2026	14 itemsAugust 2026	8 itemsSeptember 2025	−2	+4	Small n
EMA periodic safety update single assessment (PSUSA) outcomes publishedUnit: procedures	19 proceduresn = 19	September 2026	13 proceduresAugust 2026	28 proceduresSeptember 2025	+6	−9	Small n
US FDA warning letters posted (human drugs, biologics and devices)Unit: letters	28 lettersn = 28	September 2026	15 lettersAugust 2026	97 lettersSeptember 2025	+13	−69 (−71.1%)	Small n
US FDA medical device recall events first reportedUnit: recall events	101 recall events	September 2026	97 recall eventsAugust 2026	80 recall eventsSeptember 2025	+4 (+4.1%)	+21 (+26.3%)	None

Definitions, notes and sources: shortages and safety

Medicine shortages first published by EMA, 12 months

Entries in EMA's medicine shortages list whose first publication date falls in the 12 months ending with the reference month. EMA lists shortages that affect more than one EU member state or that it is coordinating; national shortages in Ireland are not included.

Note: Small counts: the list holds 85 entries in total.

Source: European Medicines Agency. Dataset ema_shortages, collected 19 October 2026. Data complete from December 2013 to September 2026.

MHRA drug and device alerts and Drug Safety Update articles (UK)

GOV.UK items from the MHRA drug and device alerts list and the Drug Safety Update whose issued date falls in the month.

Note: Comparator series (United Kingdom).

Source: Medicines and Healthcare products Regulatory Agency (MHRA), via GOV.UK. Dataset mhra_safety_alerts, collected 19 October 2026. Data complete from November 2003 to September 2026.

EMA periodic safety update single assessment (PSUSA) outcomes published

Distinct PSUSA procedure numbers whose outcome was first published by EMA in the month.

Note: The dataset starts with EMA's late-2023 publication format; earlier outcomes are not included.

Source: European Medicines Agency. Dataset ema_psusa, collected 19 October 2026. Data complete from December 2023 to September 2026.

US FDA warning letters posted (human drugs, biologics and devices)

Warning letters about human drugs, biologics or medical devices whose posted date on fda.gov falls in the month.

Note: Posted date is used rather than issue date because FDA posts letters days to weeks after issuing them.

Note: Comparator series (United States).

Source: U.S. Food and Drug Administration. Dataset fda_warning_letters, collected 19 October 2026. Data complete from February 2021 to September 2026.

US FDA medical device recall events first reported

Distinct FDA recall events (event_id) whose first appearance in the FDA Enforcement Report (report_date) falls in the month. One event can cover several products.

Note: Report date is used rather than recall initiation date, which is filled in for recent months only after FDA classifies the recall.

Note: Comparator series (United States).

Source: U.S. Food and Drug Administration (openFDA). Dataset fda_device_recalls, collected 19 October 2026. Data complete from March 2018 to September 2026.

Clinical trials

Clinical trials: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Studies with a site in Ireland starting, 12 monthsUnit: studies	132 studies	12 months to June 2026	139 studies12 months to May 2026	137 studies12 months to June 2025	−7 (−5.0%)	−5 (−3.6%)	Lag 3 months Provisional
Ireland's share of studies with a European site, 12 monthsUnit: percent	1.54%	12 months to June 2026	1.60%12 months to May 2026	1.46%12 months to June 2025	−0.06 pp	+0.08 pp	Lag 3 months Provisional

Definitions, notes and sources: clinical trials

Studies with a site in Ireland starting, 12 months

ClinicalTrials.gov studies with at least one site in Ireland whose start date (actual or anticipated, as registered) falls in the 12 months ending with the reference month. Withdrawn studies are excluded.

Note: Studies are often registered, or add an Irish site, after they start, so recent months rise in later snapshots. A three-month lag is applied and the figure is still provisional.

Source: U.S. National Library of Medicine. Dataset ctgov_ireland, collected 19 October 2026. Data complete from May 1989 to June 2026.

Ireland's share of studies with a European site, 12 months

Of ClinicalTrials.gov studies with at least one site in Europe that start in the 12 months ending with the reference month (withdrawn excluded), the percentage that also list a site in Ireland.

Note: Changes in a share are shown in percentage points.

Note: Same registration lag as the Ireland count.

Source: U.S. National Library of Medicine. Dataset ctgov_europe, collected 19 October 2026. Data complete from January 2015 to June 2026.

Trade and industry

Trade and industry: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Ireland's exports of medicinal and pharmaceutical products (SITC 54), all partnersUnit: EUR million	EUR 5,971 million	August 2026	EUR 6,789 millionJuly 2026	EUR 6,483 millionAugust 2025	−818 (−12.1%)	−513 (−7.9%)	Lag Provisional
Ireland's exports of medicinal and pharmaceutical products to the United StatesUnit: EUR million	EUR 2,150 million	August 2026	EUR 2,732 millionJuly 2026	EUR 2,387 millionAugust 2025	−582 (−21.3%)	−237 (−9.9%)	Lag Provisional
Ireland's share of EU member states' pharmaceutical exportsUnit: percent	12.4%	July 2026	12.3%June 2026	13.1%July 2025	+0.1 pp	−0.6 pp	Lag Partial month out Provisional
Industrial production index, modern sector (seasonally adjusted)Unit: index (2021 = 100)	115.7	August 2026	117.8July 2026	141.2August 2025	−2.1 (−1.8%)	−25.5 (−18.1%)	Lag Provisional

Definitions, notes and sources: trade and industry

Ireland's exports of medicinal and pharmaceutical products (SITC 54), all partners

Eurostat monthly trade value of SITC 54 exports declared by Ireland, partner WORLD, in euro million.

Note: Eurostat publishes monthly trade about six to seven weeks after the month; recent months are provisional and revised.

Note: Values are not seasonally adjusted. Monthly pharmaceutical trade is volatile.

Source: Eurostat (European Commission), Comext dataset DS-059331. Dataset eurostat_pharma_trade, collected 19 October 2026. Data complete from January 2002 to August 2026.

Ireland's exports of medicinal and pharmaceutical products to the United States

CSO table TSM10 value of SITC 54 exports from Ireland to the United States, in euro million.

Note: CSO publishes goods exports about six weeks after the month; recent months are provisional.

Note: Source values are in euro thousand; divided by 1,000.

Source: Central Statistics Office, Ireland. Dataset cso_pharma_exports, collected 19 October 2026. Data complete from January 2015 to August 2026.

Ireland's share of EU member states' pharmaceutical exports

Ireland's SITC 54 exports to all partners as a percentage of the sum of SITC 54 exports to all partners declared by the 27 EU member states (Eurostat monthly data). A month is used only when every member state has reported.

Note: Member states' exports include trade between member states, so the denominator double counts goods that move within the EU. The share describes declared exports, not EU production.

Note: Changes in a share are shown in percentage points.

Source: Eurostat (European Commission), Comext dataset DS-059331. Dataset eurostat_pharma_trade, collected 19 October 2026. Data complete from January 2002 to July 2026.

Industrial production index, modern sector (seasonally adjusted)

CSO table MIM05 industrial production volume index for the modern sector (NACE 18.2, 20, 21, 26, 27 and 32.5, which includes pharmaceuticals), seasonally adjusted, base year 2021 = 100.

Note: The modern sector is wider than pharmaceuticals (NACE 21) alone; CSO does not publish a monthly NACE 21 index in this table.

Note: CSO revises recent months.

Source: Central Statistics Office, Ireland (PxStat tables MIM05, MIA05, EHQ15, EHQ58, AIA30, PMMA01-PMMA07, PMMA10, PMMA11, PMMA13). Dataset cso_pharma_industry_stats, collected 19 October 2026. Data complete from January 2015 to August 2026.

Prescribing and spending

Prescribing and spending: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Prescription items dispensed in the community, EnglandUnit: million items	114.8 million items	July 2026	110.6 million itemsJune 2026	111.4 million itemsJuly 2025	+4.2 (+3.8%)	+3.4 (+3.1%)	Lag
Net ingredient cost of prescriptions dispensed in the community, EnglandUnit: GBP million	GBP 1,071.6 million	July 2026	GBP 1,023.2 millionJune 2026	GBP 991.1 millionJuly 2025	+48.4 (+4.7%)	+80.5 (+8.1%)	Lag
GP prescription items dispensed, Northern IrelandUnit: million items	3.64 million items	August 2026	3.92 million itemsJuly 2026	3.63 million itemsAugust 2025	−0.28 (−7.3%)	+0.00 (+0.1%)	Lag
Actual cost of GP prescribing, Northern IrelandUnit: GBP million	GBP 40.4 million	August 2026	GBP 43.3 millionJuly 2026	GBP 38.4 millionAugust 2025	−2.9 (−6.7%)	+2.0 (+5.1%)	Lag

Definitions, notes and sources: prescribing and spending

Prescription items dispensed in the community, England

Sum of items over all BNF chemical substances in NHSBSA Prescription Cost Analysis for the month, in millions.

Note: NHSBSA publishes about two months after the month.

Note: Month-on-month changes reflect the number of working days in each month.

Source: NHS Business Services Authority (NHSBSA), Open Data Portal, dataset "Prescription Cost Analysis (PCA) Monthly Administrative Data". Dataset nhs_prescription_costs, collected 19 October 2026. Data complete from January 2023 to July 2026.

Net ingredient cost of prescriptions dispensed in the community, England

Sum of net ingredient cost (list price before discounts, excluding fees) over all BNF chemical substances for the month, GBP million.

Note: Net ingredient cost is not the actual cost to the NHS.

Source: NHS Business Services Authority (NHSBSA), Open Data Portal, dataset "Prescription Cost Analysis (PCA) Monthly Administrative Data". Dataset nhs_prescription_costs, collected 19 October 2026. Data complete from January 2023 to July 2026.

GP prescription items dispensed, Northern Ireland

Sum of items over all rows of the BSO GP prescribing data for the month, in millions.

Note: The BSO publishes about two months after the month.

Source: Business Services Organisation (HSC Northern Ireland), OpenDataNI dataset "GP Prescribing Data". Dataset ni_bso_gp_prescribing, collected 20 October 2026. Data complete from September 2023 to August 2026.

Actual cost of GP prescribing, Northern Ireland

Sum of actual cost over all rows of the BSO GP prescribing data for the month, GBP million.

Source: Business Services Organisation (HSC Northern Ireland), OpenDataNI dataset "GP Prescribing Data". Dataset ni_bso_gp_prescribing, collected 20 October 2026. Data complete from September 2023 to August 2026.

Hospitals and waiting lists

Hospitals and waiting lists: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
People waiting for a first outpatient appointment, IrelandUnit: people	692,524 people	September 2026 (snapshot 24 September 2026)	687,839 peopleAugust 2026	626,521 peopleSeptember 2025	+4,685 (+0.7%)	+66,003 (+10.5%)	None
People waiting for an inpatient or day case procedure, Ireland (GI endoscopy excluded)Unit: people	114,722 people	September 2026 (snapshot 24 September 2026)	114,921 peopleAugust 2026	100,045 peopleSeptember 2025	−199 (−0.2%)	+14,677 (+14.7%)	None
People waiting for GI endoscopy, IrelandUnit: people	43,288 people	September 2026 (snapshot 24 September 2026)	42,725 peopleAugust 2026	33,786 peopleSeptember 2025	+563 (+1.3%)	+9,502 (+28.1%)	None
People waiting 18 months or more, all three NTPF listsUnit: people	64,077 people	September 2026 (snapshot 24 September 2026)	62,188 peopleAugust 2026	54,104 peopleSeptember 2025	+1,889 (+3.0%)	+9,973 (+18.4%)	None

Definitions, notes and sources: hospitals and waiting lists

People waiting for a first outpatient appointment, Ireland

Sum of total waiting over all hospitals in NTPF report OPNational01 (outpatient by hospital, adult and child), latest snapshot in the month.

Note: Snapshot dates are the last Thursday of the month or close to it; the date used is shown.

Source: National Treatment Purchase Fund (NTPF), Ireland. Dataset ntpf_waiting_lists, collected 19 October 2026. Data complete from October 2024 to September 2026.

People waiting for an inpatient or day case procedure, Ireland (GI endoscopy excluded)

Sum of total waiting over all hospitals in NTPF report IPDCNational01 (inpatient/day case by hospital, adult and child), latest snapshot in the month.

Source: National Treatment Purchase Fund (NTPF), Ireland. Dataset ntpf_waiting_lists, collected 19 October 2026. Data complete from October 2024 to September 2026.

People waiting for GI endoscopy, Ireland

Sum of total waiting over all hospitals in NTPF report IPDCNational04 (GI endoscopy by hospital), latest snapshot in the month.

Source: National Treatment Purchase Fund (NTPF), Ireland. Dataset ntpf_waiting_lists, collected 19 October 2026. Data complete from October 2024 to September 2026.

People waiting 18 months or more, all three NTPF lists

Sum of waiting_18_plus_months over NTPF reports OPNational01, IPDCNational01 and IPDCNational04 (outpatient, inpatient/day case and GI endoscopy, by hospital), latest snapshot in the month.

Note: A person on more than one list is counted once per list.

Source: National Treatment Purchase Fund (NTPF), Ireland. Dataset ntpf_waiting_lists, collected 19 October 2026. Data complete from October 2024 to September 2026.

Research and funding

Research and funding: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
EU-funded health research projects with an Irish participant starting, 12 monthsUnit: projects	79 projects	12 months to September 2026	72 projects12 months to August 2026	85 projects12 months to September 2025	+7 (+9.7%)	−6 (−7.1%)	Provisional
Ireland's share of European pharmacology and drug discovery publications, 12 monthsUnit: percent	1.85%	12 months to July 2026	1.90%12 months to June 2026	1.92%12 months to July 2025	−0.05 pp	−0.06 pp	Lag 2 months Provisional
Research Ireland and SFI grant commitments starting in the yearUnit: grant records	626 grant records	2025	Annual series	652 grant records2024	Annual series	−26 (−4.0%)	Provisional

Definitions, notes and sources: research and funding

EU-funded health research projects with an Irish participant starting, 12 months

CORDIS Horizon 2020 and Horizon Europe health projects with at least one organisation in Ireland (participant country IE, any role) whose start date falls in the 12 months ending with the reference month.

Note: Projects appear in CORDIS when the grant is signed, which can be after the start date; recent months can rise.

Source: European Commission / Publications Office of the European Union (CORDIS). Dataset cordis_health, collected 15 October 2026. Data complete from January 2015 to September 2026.

Ireland's share of European pharmacology and drug discovery publications, 12 months

Of OpenAlex works in the European pharmacology, pharmaceutics, toxicology and drug discovery set (EU-27, UK, Norway, Switzerland) published in the 12 months ending with the reference month, the percentage with an author affiliation in Ireland (country IE).

Note: OpenAlex indexes works some weeks after publication; a two-month lag is applied.

Note: Works without a full publication date are often dated 1 January, which inflates January; the 12-month window absorbs this.

Note: Changes in a share are shown in percentage points.

Source: OurResearch (OpenAlex). Dataset openalex_europe_pharma, collected 19 October 2026. Data complete from January 2023 to July 2026.

Research Ireland and SFI grant commitments starting in the year

Rows of the Research Ireland and Science Foundation Ireland grant commitment files with a positive amount whose start date falls in the calendar year.

Note: Annual series; only year-on-year change applies.

Note: The current Research Ireland file is published irregularly and ran to January 2026 when collected; grants that started in 2025 can still be added.

Note: From August 2024 the source file changed (SFI to Research Ireland), and supplements are no longer separate rows; counts either side of that change are not strictly comparable.

Source: Taighde Éireann – Research Ireland (formerly Science Foundation Ireland and the Irish Research Council; Irish Research Council grants not included). Dataset research_ireland_grants, collected 20 October 2026. Data complete from 2002 to 2025.

Policy

Policy: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Parliamentary questions on medicines, drugs, pharmaceuticals and the HPRAUnit: questions	223 questionsn = 223	September 2026	0 questionsAugust 2026	145 questionsSeptember 2025	+223	+78 (+53.8%)	Small n

Definitions, notes and sources: policy

Parliamentary questions on medicines, drugs, pharmaceuticals and the HPRA

Oireachtas parliamentary questions (written and oral) to the Departments of Health and Enterprise matching the medicines topic terms, by date in the official record.

Note: The Dáil does not sit in August and sits less in December; zero or low counts in those months reflect the sitting calendar.

Note: Year-on-year comparison is the more informative one for this series.

Source: Houses of the Oireachtas, Oireachtas Open Data API. Dataset oireachtas_medicine_questions, collected 20 October 2026. Data complete from April 2020 to September 2026.

Procurement

Procurement: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Health contract awards published on eTenders, IrelandUnit: awards	39 awards	September 2026	64 awardsAugust 2026	31 awardsSeptember 2025	−25 (−39.1%)	+8 (+25.8%)	None
Share of health contract awards with at least one SME supplier, 12 monthsUnit: percent	73.2%	12 months to September 2026	73.5%12 months to August 2026	73.9%12 months to September 2025	−0.3 pp	−0.6 pp	None

Definitions, notes and sources: procurement

Health contract awards published on eTenders, Ireland

Distinct health procurement notices or contracts (tender_id and title) on eTenders whose award published date falls in the month.

Note: Not every contract has an award notice on eTenders; the series counts published awards only.

Source: Office of Government Procurement (OGP), Ireland. Dataset etenders_health_awards, collected 20 October 2026. Data complete from May 2013 to September 2026.

Share of health contract awards with at least one SME supplier, 12 months

Of distinct health awards on eTenders (tender_id and title, each counted once) whose award published date falls in the 12 months ending with the reference month and that publish a number of awarded SMEs, the percentage with one or more awarded SMEs.

Note: Awarded contract values are not used as an indicator: framework and panel awards publish ceiling values (up to EUR 700 million for one award), so a monthly or 12-month total is dominated by a handful of notices.

Note: Changes in a share are shown in percentage points.

Source: Office of Government Procurement (OGP), Ireland. Dataset etenders_health_awards, collected 20 October 2026. Data complete from July 2013 to September 2026.

Environment

Environment: latest complete period for each indicator

Indicator	Value	Reference period	Previous	Year earlier	Month on month	Year on year	Flags
Waste transferred off site by Irish chemical and pharmaceutical facilities (annual)Unit: tonnes	253,821 tonnes	2024	Annual series	508,328 tonnes2023	Annual series	−254,506 (−50.1%)	Lag

Definitions, notes and sources: environment

Waste transferred off site by Irish chemical and pharmaceutical facilities (annual)

Sum of quantity (tonnes) of waste transfer records reported to EEA Industrial Reporting (E-PRTR) by the Irish chemical and pharmaceutical facilities in the dataset, by reporting year.

Note: Annual series; only year-on-year change applies. EEA publishes a reporting year about 15 to 18 months after it ends.

Note: Only facilities above E-PRTR reporting thresholds report.

Source: European Environment Agency (EEA), Industrial Reporting under the Industrial Emissions Directive 2010/75/EU and the E-PRTR Regulation (EC) No 166/2006 (Irish data reported by the EPA). Dataset eea_industrial_emissions_ireland, collected 20 October 2026. Data complete from 2007 to 2024.

Projections

Statistical projection based on past patterns. Not a prediction of events and not advice.

A series gets a projection only when its model passed every test below in rolling-origin backtests: the model is refitted at 12 past cut-off points, projects 6 months ahead each time, and is scored against what the data then showed.

• Error (MASE) below 1, and at least 5% lower than the better of two simple benchmarks: seasonal naive (same month last year) and naive (last month).
• The 80% band contained at least 65% of the backtest outcomes.
• At least 36 complete months of history, and for counts an average of at least 10 events a month.

Bands show 80% and 95% intervals. Models tried: SeasonalNaive, Naive, AutoETS, AutoARIMA, AutoTheta, Combination. Equal-weight mean of AutoETS, AutoARIMA and AutoTheta; its intervals are the average of the three component intervals.

Published projections: chosen model and backtest results

Series	History used	Chosen model	MASE	Best benchmark MASE	Better than benchmark	80% band coverage	95% band coverage
Prescription items dispensed in the community, England	43 months, January 2023 to July 2026	AutoARIMA	0.651	0.827SeasonalNaive	21%	89%	96%
Studies with a site in Ireland starting in the month (ClinicalTrials.gov) Provisional: late registrations still arriving	120 months, April 2016 to March 2026	AutoARIMA	0.605	0.721SeasonalNaive	16%	85%	100%
Studies with a site in Europe starting in the month (ClinicalTrials.gov) Provisional: late registrations still arriving	120 months, April 2016 to March 2026	AutoETS	0.681	0.837SeasonalNaive	19%	88%	94%
US FDA original approvals, all application types	120 months, October 2016 to September 2026	AutoTheta	0.409	0.448Naive	9%	92%	100%
US FDA original approvals of new drug and biologic applications (NDA and BLA)	120 months, October 2016 to September 2026	AutoTheta	0.725	0.918SeasonalNaive	21%	89%	97%

Prescription items dispensed in the community, England

Sum of items over all BNF chemical substances in NHSBSA Prescription Cost Analysis for the month. Source: NHS Business Services Authority (NHSBSA), Open Data Portal, dataset "Prescription Cost Analysis (PCA) Monthly Administrative Data", dataset nhs_prescription_costs, collected 19 October 2026. Decision: MASE 0.651 < 1; 21% better than the best naive benchmark; 80% interval coverage 89% >= 65%.

Projection, million items (AutoARIMA)

Month	Median	80% band	95% band
August 2026	105	101 to 109	99.0 to 111
September 2026	111	106 to 116	104 to 118
October 2026	123	118 to 127	116 to 130
November 2026	108	104 to 113	101 to 115
December 2026	118	113 to 122	111 to 125
January 2027	113	108 to 118	106 to 120

Studies with a site in Ireland starting in the month (ClinicalTrials.gov)

Provisional: late registrations still arriving

ClinicalTrials.gov studies with at least one site in Ireland whose start date falls in the month. Withdrawn studies excluded. Source: U.S. National Library of Medicine, dataset ctgov_ireland, collected 19 October 2026. Decision: MASE 0.605 < 1; 16% better than the best naive benchmark; 80% interval coverage 85% >= 65%.

Note: Studies are often registered, or add a site, after they start, so recent months rise in later snapshots. A six-month lag is applied (the descriptive report uses three) so the model is not fitted to the most understated months; the latest months used are still provisional.

Note: Lag of 6 months applied after the collection date 2026-10-19.

Projection, studies (AutoARIMA)

Month	Median	80% band	95% band
April 2026	10.9	6.12 to 15.8	3.56 to 18.3
May 2026	11.8	7.02 to 16.7	4.47 to 19.2
June 2026	12.6	7.80 to 17.4	5.25 to 20.0
July 2026	11.3	6.44 to 16.1	3.89 to 18.6
August 2026	12.2	7.34 to 17.0	4.79 to 19.5
September 2026	11.3	6.50 to 16.1	3.95 to 18.7

Studies with a site in Europe starting in the month (ClinicalTrials.gov)

Provisional: late registrations still arriving

ClinicalTrials.gov studies with at least one site in the EU-27, UK, Norway, Iceland, Switzerland or Liechtenstein whose start date falls in the month. Withdrawn studies excluded. Source: U.S. National Library of Medicine, dataset ctgov_europe, collected 19 October 2026. Decision: MASE 0.681 < 1; 19% better than the best naive benchmark; 80% interval coverage 88% >= 65%.

Note: Same registration lag as the Ireland series; the dataset covers studies starting 2015 or later.

Note: Lag of 6 months applied after the collection date 2026-10-19.

Projection, studies (AutoETS)

Month	Median	80% band	95% band
April 2026	708	630 to 786	589 to 827
May 2026	720	640 to 800	598 to 842
June 2026	738	656 to 820	613 to 863
July 2026	595	512 to 678	469 to 722
August 2026	491	407 to 575	363 to 619
September 2026	802	716 to 888	670 to 933

US FDA original approvals, all application types

Drugs@FDA applications (NDA, BLA and ANDA) whose original approval date falls in the month. Source: U.S. Food and Drug Administration (openFDA), dataset fda_approvals, collected 19 October 2026. Decision: MASE 0.409 < 1; 9% better than the best naive benchmark; 80% interval coverage 92% >= 65%.

Projection, applications (AutoTheta)

Month	Median	80% band	95% band
October 2026	68.4	50.0 to 87.4	40.3 to 93.5
November 2026	68.4	50.8 to 85.2	44.1 to 97.9
December 2026	68.3	46.4 to 86.5	41.1 to 96.7
January 2027	68.3	48.1 to 88.1	39.3 to 97.7
February 2027	68.2	49.8 to 82.8	34.3 to 94.8
March 2027	68.2	47.7 to 86.6	38.0 to 96.7

US FDA original approvals of new drug and biologic applications (NDA and BLA)

Drugs@FDA applications of type NDA or BLA whose original approval date falls in the month. Source: U.S. Food and Drug Administration (openFDA), dataset fda_approvals, collected 19 October 2026. Decision: MASE 0.725 < 1; 21% better than the best naive benchmark; 80% interval coverage 89% >= 65%.

Projection, applications (AutoTheta)

Month	Median	80% band	95% band
October 2026	11.8	6.38 to 17.4	3.52 to 19.2
November 2026	11.8	6.73 to 16.8	5.04 to 20.5
December 2026	11.8	6.18 to 17.2	4.30 to 20.0
January 2027	11.8	5.96 to 17.4	2.98 to 20.2
February 2027	11.8	6.67 to 15.9	3.41 to 19.4
March 2027	11.8	6.48 to 16.9	3.83 to 20.2

Series assessed and not projected

Other series tested this edition

Series	Decision	Reason
Ireland's exports of medicinal and pharmaceutical products, all destinations	Seasonal pattern only; no projection	Benchmark Naive had the lowest backtest MASE (2.892); no model beat it.
Net ingredient cost of prescriptions dispensed in the community, England	Seasonal pattern only; no projection	Chosen model MASE 1.151 is not below 1.
GP prescription items dispensed, Northern Ireland	Seasonal pattern only; no projection	Benchmark SeasonalNaive had the lowest backtest MASE (1.323); no model beat it.
Actual cost of GP prescribing, Northern Ireland	Seasonal pattern only; no projection	Chosen model MASE 1.359 is not below 1.
People on the NTPF waiting list: Outpatient (first appointment), Ireland	Not projected (insufficient history)	24 complete months; at least 36 required.
People on the NTPF waiting list: Inpatient/day case (GI endoscopy excluded), Ireland	Not projected (insufficient history)	24 complete months; at least 36 required.
People on the NTPF waiting list: GI endoscopy, Ireland	Not projected (insufficient history)	24 complete months; at least 36 required.
Medicine shortages first published by EMA in the month	Low count: observed rate only, no projection	Mean monthly count 0.62 is below 10.

Accuracy log

No projection has been scored yet. This is the first edition with projections. In later editions, each published projection will be compared with the figures as they then appear in the data, and the error will be listed here next to the month it refers to. Projections that miss will stay on this list.

Methods

• Computed by code. Figures come from airmed tools/monthly_trends.py version 1.0.0 with the definitions file trends_indicators.json version 1.0.0. Each indicator has a fixed definition, unit, dataset, date field, filter and aggregation, listed with its figures in the downloads.
• Reference periods. Each indicator uses its own latest complete period ending before the edition month. Publication lags are stated as flags.
• Complete months only. Period datasets only: a month is complete when the number of distinct key values reaches min_ratio x the highest number seen in the previous 12 months. Months to step back from the last month that ended before collection, because the publisher adds records for a month some time after it ends.
• Changes. Month-on-month and year-on-year, only when both periods are complete; percentage changes withheld below min_n; shares change in percentage points.
• Small counts. If the count behind a figure, or behind a comparison period, is below min_n, percentage changes are not given and the indicator is flagged small_n.
• Describe, not explain. Figures describe the data; no causes, predictions or medical advice.
• Windows and aggregation. 1 = the reference month alone; 12 = the 12 months ending with the reference month (all 12 must be complete). Count = rows; count_distinct = distinct values of keys; sum = sum of a numeric field; share = 100 x numerator / denominator, where the numerator is the denominator rows that also pass numerator_filter; value = the single published value of each period.
• Projections. Module version 1.0.0, libraries python 3.12.10, numpy 2.5.2, pandas 2.3.3, scipy 1.18.1, statsforecast 2.1.1. MASE is scaled by in-sample seasonal naive (lag 12) MAE of each backtest training window. Intervals and medians are floored at zero (all series are non-negative).

Limitations

• Revisions. Figures flagged provisional (trade, production, trials, CORDIS projects and publications among them) change in later releases. This edition uses one release, so it cannot measure revision size.
• Registers are snapshots. The HPRA register lists current products, so withdrawn products drop out of earlier months, and the latest month can rise when products are added late.
• Narrow definitions. The modern sector index is wider than pharmaceuticals. EMA shortages are the shortages EMA lists for the EU, not Irish national shortages. NTPF totals count a person once per list. Member states' export totals include trade between member states.
• Gaps. Airmid has no Irish national shortage data and no monthly Irish prescribing data. The annual GMS prescribing indicators are held from this edition while their published unit labels are confirmed.
• One-off base months. Some year-on-year changes, such as FDA warning letters and the modern sector production index, compare with unusually high months in their series. The charts show this.
• Trial projections. The trial-start projections cover months whose registrations are still arriving, so their outcomes keep rising in later snapshots.

Data and code

• Data: Airmid Éireann: Ireland's Open Pharma Data Project, release 1.3.0 (21 October 2026), DOI 10.5281/zenodo.23499798. Browse it at Airmid Éireann or download it from /opendata/airmid/v1/. Catalogue SHA-256 68e049ff785a1c3367a6b0d6b01e07e0fb126b412dc1921e7445cc11aa23b99a.
• Indicator code: tools/monthly_trends.py (SHA-256 2bc1464cb431bf97e6633a61d62fc2acccf497558e7e27737b026b5ab3e29f4a) and tools/trends_indicators.json (SHA-256 2523fc5a5f280a662e59acf4ee67b668ae615120a6f0fd31b8c5e04176bf58f0), pandas 2.3.3.
• Projection code: tools/monthly_forecast.py (SHA-256 21fea800a63bdff872408acea568d52d83d67e188ed8bc4acf22305c36779c94).
• Anyone with the same data release and code gets the same numbers: every dataset below is recorded with its collection time and the SHA-256 of the file used.

• Edition data (JSON)
• Indicators (CSV)
• Series (CSV)
• Projections (CSV)

Sources

Datasets used in this edition, with publisher and licence

Dataset	Publisher	Licence	Collected	Records
CORDIS: EU-funded health, medicine, pharma and biotech research projects (Horizon 2020 and Horizon Europe)cordis_health	European Commission / Publications Office of the European Union (CORDIS)	European Commission reuse notice (Decision 2011/833/EU); CC BY 4.0 per CORDIS legal notice ("the reuse of the editorial…Source: CORDIS, European Commission / Publications Office of the European Union, CC BY 4.0. Filtered to health projects and reduced to project-level fields by Airmid Éireann.	15 October 2026	14,111
CSO: Irish exports of medicinal and pharmaceutical products by country (TSM10)cso_pharma_exports	Central Statistics Office, Ireland	CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). CSO copyright policy: "Statistical information on this websit…Source: Central Statistics Office, Ireland (table TSM10), CC BY 4.0.	19 October 2026	6,860
CSO: Irish pharmaceutical industry statistics (NACE 21): production indices, earnings, Census of Industrial Production, Pharmaceutical and Medical Manufacturing seriescso_pharma_industry_stats	Central Statistics Office, Ireland (PxStat tables MIM05, MIA05, EHQ15, EHQ58, AIA30, PMMA01-PMMA07, PMMA10, PMMA11, PMMA13)	CC BY 4.0. CSO copyright policy: statistical information on the CSO website is "accessible free of charge" and "license…Source: Central Statistics Office, Ireland (tables MIM05, MIA05, EHQ15, EHQ58, AIA30, PMMA01-PMMA07, PMMA10, PMMA11, PMMA13), CC BY 4.0. Reshaped to long format by Airmid Éireann; CSO's confidentiality marker -99999999 is shown as an empty value with status 'confidential'.	19 October 2026	1,905
ClinicalTrials.gov: studies with a site in Europe, started 2015 or laterctgov_europe	U.S. National Library of Medicine	ClinicalTrials.gov Terms and Conditions (NLM). Data carry an international copyright outside the United States; reuse i…Source: ClinicalTrials.gov, a U.S. Government database of the U.S. National Library of Medicine. Data processed by ClinicalTrials.gov as retrieved on 2026-10-19. Modifications by Airmid Éireann: only studies with at least one site in the EU-27, UK, Norway, Iceland, Switzerland or Liechtenstein that started on or after 2015-01-01; only the fields nct_id, title, phases, overall_status, lead_sponsor, conditions, start_date, last_update and countries (European countries only) kept; contacts, investigators, officials, facility names, cities and coordinates not downloaded; lead sponsors that ClinicalTrials.gov does not class as industry, government or network and whose name does not read as an organisation blanked (possible personal names). This is a dated snapshot and may not be current; check ClinicalTrials.gov.	19 October 2026	113,437
ClinicalTrials.gov: studies with a site in Irelandctgov_ireland	U.S. National Library of Medicine	ClinicalTrials.gov Terms and Conditions (NLM). Data carry an international copyright outside the United States; reuse i…Source: ClinicalTrials.gov, a U.S. Government database of the U.S. National Library of Medicine. Data processed by ClinicalTrials.gov as retrieved on 2026-10-19. Modifications by Airmid Éireann: only studies with at least one site in Ireland (all statuses); only the fields nct_id, title, phases, overall_status, lead_sponsor, conditions, start_date and last_update kept; contacts, investigators, officials and site details not downloaded; lead sponsors that ClinicalTrials.gov does not class as industry, government or network and whose name does not read as an organisation blanked (possible personal names). This is a dated snapshot and may not be current; check ClinicalTrials.gov.	19 October 2026	2,699
EEA Industrial Reporting (E-PRTR): pollutant releases and waste transfers of Irish chemical and pharmaceutical facilitieseea_industrial_emissions_ireland	European Environment Agency (EEA), Industrial Reporting under the Industrial Emissions Directive 2010/75/EU and the E-PRTR Regulation (EC) No 166/2006 (Irish data reported by the EPA)	Creative Commons Attribution 4.0 International (EEA SDI catalogue record for the dataset, ver. 16.0 Feb. 2026: "License…Source: European Environment Agency, Industrial Reporting under the Industrial Emissions Directive 2010/75/EU and European Pollutant Release and Transfer Register Regulation (EC) No 166/2006 (https://www.eea.europa.eu/en/datahub/datahubitem-view/9405f714-8015-4b5b-a63c-280b82861b3d), licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Copyright holder: European Environment Agency (EEA). Filtered to Irish facilities in E-PRTR Annex I section 4 (chemical industry) and reshaped by Airmid Éireann. Not endorsed by the EEA or the EPA.	20 October 2026	19,871
EMA: human medicines evaluated by the European Medicines Agencyema_medicines	European Medicines Agency	EMA legal notice: information and documents on EMA's webpages "may be reproduced and/or distributed, totally or in part…Source: European Medicines Agency (EMA).	19 October 2026	2,357
EMA: EU orphan designationsema_orphans	European Medicines Agency	EMA legal notice: information and documents on EMA's webpages "may be reproduced and/or distributed, totally or in part…Source: European Medicines Agency (EMA).	19 October 2026	3,310
EMA: periodic safety update single assessment (PSUSA) outcomesema_psusa	European Medicines Agency	EMA legal notice: information and documents on EMA's webpages "may be reproduced and/or distributed, totally or in part…Source: European Medicines Agency (EMA), PSUSA outcomes.	19 October 2026	2,735
EMA: medicine shortages (human)ema_shortages	European Medicines Agency	EMA legal notice: information and documents on EMA's webpages "may be reproduced and/or distributed, totally or in part…Source: European Medicines Agency (EMA).	19 October 2026	85
eTenders (Ireland): public procurement notices and contract awards in health, medicines and medical technology, 2013 onwardsetenders_health_awards	Office of Government Procurement (OGP), Ireland	Creative Commons Attribution 4.0 International (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/). data.gov.ie l…Source: Office of Government Procurement, Contract Notices Published on eTenders, via data.gov.ie. Contains Irish Public Sector Data licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Changed by Airmid Éireann: filtered to health (CPV 33 / 85 / 851 and health contracting authorities), supplier names without a company or public-body marker withheld, dates converted to ISO, amounts to numbers.	20 October 2026	6,914
Eurostat: EU member states' trade in medicinal and pharmaceutical products (SITC 54), by partnereurostat_pharma_trade	Eurostat (European Commission), Comext dataset DS-059331	Eurostat free re-use policy (Commission Decision 2011/833/EU; editorial content CC BY 4.0): "Reuse of statistical data,…Source: Eurostat, International trade of EU and non-EU countries since 2002 by SITC (DS-059331), product SITC 54. Compiled into long format by Airmid Éireann (filtered to SITC 54, value in euro, EU27 reporters). Data modified by Airmid Éireann (filtered and reshaped). Eurostat has no responsibility for this reuse or for any errors in it.	19 October 2026	207,276
US FDA: original approvals, all years (Drugs@FDA)fda_approvals	U.S. Food and Drug Administration (openFDA)	Public domain (U.S. government work); see openFDA termsSource: U.S. Food and Drug Administration, Drugs@FDA via openFDA. Not endorsed by the FDA.	19 October 2026	25,405
US FDA: medical device recalls since 2018fda_device_recalls	U.S. Food and Drug Administration (openFDA)	Public domain, CC0 1.0 (openFDA terms: "Unless otherwise noted, the content, data, documentation, code, and related mat…Data provided by the U.S. Food and Drug Administration (https://open.fda.gov). Not endorsed by the FDA. openFDA: "Do not rely on openFDA to make decisions regarding medical care."	19 October 2026	23,868
US FDA: warning letters about human drugs, biologics and medical devices (2021 onwards)fda_warning_letters	U.S. Food and Drug Administration	Public domain, U.S. government work (FDA website policies: "Unless otherwise noted, the contents of the FDA website (ww…Source: U.S. Food and Drug Administration, warning letters listing (fda.gov). Not endorsed by the FDA. A warning letter states FDA's view at the time it was issued; check the letter and any close-out letter on fda.gov before relying on it.	19 October 2026	1,729
HPRA: human medicines authorised in Irelandhpra_medicines	Health Products Regulatory Authority	CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), as listed on data.gov.ie: dataset "Human Medicines - Authoris…Source: Health Products Regulatory Authority (HPRA), CC BY 4.0.	19 October 2026	10,290
MHRA (UK): drug and device alerts and Drug Safety Updatemhra_safety_alerts	Medicines and Healthcare products Regulatory Agency (MHRA), via GOV.UK	Open Government Licence v3.0 (GOV.UK reuse: "To reuse content published on GOV.UK you must meet the conditions of the O…Contains public sector information licensed under the Open Government Licence v3.0. Source: Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK (https://www.gov.uk/help/reuse-govuk-content).	19 October 2026	2,323
NHS England Prescription Cost Analysis: monthly items and cost by BNF chemical substancenhs_prescription_costs	NHS Business Services Authority (NHSBSA), Open Data Portal, dataset "Prescription Cost Analysis (PCA) Monthly Administrative Data"	Open Government Licence v3.0 (the dataset's licence on the NHSBSA portal: "Open Government Licence 3.0 (United Kingdom)…Contains public sector information licensed under the Open Government Licence v3.0. Source: NHS Business Services Authority, Prescription Cost Analysis (PCA) Monthly Administrative Data (https://opendata.nhsbsa.net/dataset/prescription-cost-analysis-pca-monthly-data). Summed by BNF chemical substance and unit of measure by Airmid Éireann. Monthly PCA is management information, not an Official Statistic.	19 October 2026	115,814
Northern Ireland GP prescribing: monthly items and cost by BNF chemical substance and formulationni_bso_gp_prescribing	Business Services Organisation (HSC Northern Ireland), OpenDataNI dataset "GP Prescribing Data"	Open Government Licence v3.0 (the dataset's licence on OpenDataNI: "UK Open Government Licence (OGL)", licence_id uk-og…Contains public sector information licensed under the Open Government Licence v3.0. Source: Business Services Organisation (HSC NI), GP Prescribing Data on OpenDataNI (https://admin.opendatani.gov.uk/dataset/gp-prescribing-data). Summed to Northern Ireland by BNF chemical substance and presentation by Airmid Éireann. User guidance: https://gpdatasets.hscni.net/.	20 October 2026	86,689
NTPF: Irish public hospital waiting lists (outpatient, inpatient/day case, GI endoscopy), latest 24 monthly snapshotsntpf_waiting_lists	National Treatment Purchase Fund (NTPF), Ireland	NTPF Re-use of Public Sector Information terms (S.I. 279 of 2005): "You may re-use the information on this website, fre…Source: National Treatment Purchase Fund (NTPF), Open Data waiting list reports, https://www.ntpf.ie/waiting-list-data/open-data/. © National Treatment Purchase Fund. Repeated rows in the source files were summed; nothing else was changed.	19 October 2026	9,924
Oireachtas: parliamentary questions on medicines, drugs, pharmaceuticals and the HPRA (Health and Enterprise), 2020 onwardoireachtas_medicine_questions	Houses of the Oireachtas, Oireachtas Open Data API	Oireachtas (Open Data) PSI Licence, "Licence incorporating the Creative Commons Attribution 4.0 International License f…Source: Houses of the Oireachtas, Oireachtas Open Data API (https://api.oireachtas.ie/). © Houses of the Oireachtas. Re-used under the Oireachtas (Public Sector Information – Open Data) Licence (https://www.oireachtas.ie/en/open-data/license/), which incorporates CC BY 4.0. Filtered by topic and with the asking member's name removed by Airmid Éireann; the official record at data.oireachtas.ie is authoritative.	20 October 2026	10,323
OpenAlex: European-affiliated research (EU-27, UK, Norway, Switzerland) in pharmacology, pharmaceutics, toxicology and drug discovery (2023 onwards)openalex_europe_pharma	OurResearch (OpenAlex)	CC0 1.0 (public domain dedication)Source: OpenAlex (OurResearch), CC0. Filtered to European-affiliated (EU-27, UK, Norway, Switzerland) pharmacology, pharmaceutics, toxicology and medicinal chemistry works by Airmid Éireann.	19 October 2026	86,168
Research Ireland (formerly Science Foundation Ireland): research grant commitments, 2000 to the latest published file (Irish Research Council grants not included)research_ireland_grants	Taighde Éireann – Research Ireland (formerly Science Foundation Ireland and the Irish Research Council; Irish Research Council grants not included)	Creative Commons Attribution 4.0 International (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/). data.gov.ie l…Source: Taighde Éireann – Research Ireland, Grant Commitments open data (and the Science Foundation Ireland Grant Commitments file, 2000–July 2024), via data.gov.ie, CC BY 4.0. Changed by Airmid Éireann: lead applicant names and ORCID iDs removed, personal names in titles replaced by "[name withheld]", dates converted to ISO and amounts to numbers.	20 October 2026	8,475

More reports in the edition archive.